The Information reported that OpenEvidence considered raising $200 million at a $20 billion valuation but was likely to skip the round because of dilution for founders and shareholders. Annualised revenue reached about $300 million and doubled in seven months.
Why it matters
OpenEvidence shows a rarer 2026 story: a fast-growing company may decline expensive capital to avoid dilution.
What investors should watch
That can be a sign of discipline if the business can keep scaling without the new round.
This article is market context, not investment advice and not a promise of returns. It highlights where capital is moving, which companies are reaching the next stage, and which risks should be checked before any decision.
Source: beckershospitalreview.com